Hepatorenal Syndrome Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hepatorenal Syndrome Treatment Market Analysis
The hepatorenal syndrome treatment market is projected to record a CAGR of nearly 6.2% over the forecast period. Hepatorenal syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. As the kidneys stop functioning, toxins begin to build up in the body. Eventually, this leads to liver failure. The major factor attributing to the growth of the market is the increase in the prevalence of liver damage and cirrhosis. According to the Centers for Disease Control and Prevention, 4.5 million adults are diagnosed with chronic liver disease in the year 2018, in the United States alone. Furthermore, increasing fast-track and orphan drug designations boosts the market growth. However, side effects with the drugs and stringent regulations are restraining the market growth.
Hepatorenal Syndrome Treatment Market Trends
This section covers the major market trends shaping the Hepatorenal Syndrome Treatment Market according to our research experts:
Therapuetics Segment is the Fastest Growing Segment of the Hepatorenal Syndrome Treatment Market.
The therapeutics segment is expected to grow at a greater phase as the patients prefer taking drugs than undergoing surgeries. Furthermore, increasing fast track and orphan designations to the drugs is further boosting the segment. Several drugs have received orphan drug designation, thereby accelerating their approval process, and this can act as a factor pushing the growth of the therapeutics segment. For instance, in November 2018, BioVie Inc. announced that the FDA granted Orphan Drug designation to its Terlipressin drug for the treatment of the hepatorenal syndrome. The designation for orphan drugs allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials, along with seven years of market exclusivity upon regulatory approval. This is likely to drive the hepatorenal syndrome treatment market during the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors, such as the presence of key players, established healthcare infrastructure, increased prevalence of severe liver damage and cirrhosis are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to the US Department of Health and Human Services,1 in 400 adults in the United States has cirrhosis for the year 2018. As per the statistics the increasing patient pool and increasing disposable revenue in this country boost the market growth of the region.
Hepatorenal Syndrome Treatment Industry Overview
The hepatorenal syndrome treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, New Medicon Pharma Lab, Becton, Dickinson and Company, Edwards Lifesciences Corporation, Aetna Inc.,Baxter, Fuji Systems Corp, Johnson & Johnson Co, G Surgiwear Ltd.
Hepatorenal Syndrome Treatment Market Leaders
Cumberland Pharmaceuticals Inc.
Mallinckrodt Pharmaceuticals
New Medicon Pharma Lab
Becton, Dickinson and Company
Edwards Lifesciences Corporation
*Disclaimer: Major Players sorted in no particular order
Hepatorenal Syndrome Treatment Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Prevalence of Severe Liver Damage Which Often Leads to Hepatorenal Syndrome
-
4.2.2 Increasing Fast Track and Orphan Drug Designations
-
-
4.3 Market Restraints
-
4.3.1 Side-effects and Risks Related to Drug Usage
-
4.3.2 Stringent Regulatory Requirements
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Treatment
-
5.1.1 Therapeutics
-
5.1.2 Liver Transplantation
-
5.1.3 Surgical Shunting
-
5.1.4 Renal Replacement Therapy
-
5.1.5 Other Treatments
-
-
5.2 Geography
-
5.2.1 North America
-
5.2.1.1 United States
-
5.2.1.2 Canada
-
5.2.1.3 Mexico
-
-
5.2.2 Europe
-
5.2.2.1 Germany
-
5.2.2.2 United Kingdom
-
5.2.2.3 France
-
5.2.2.4 Italy
-
5.2.2.5 Spain
-
5.2.2.6 Rest of Europe
-
-
5.2.3 Asia-Pacific
-
5.2.3.1 China
-
5.2.3.2 Japan
-
5.2.3.3 India
-
5.2.3.4 Australia
-
5.2.3.5 South Korea
-
5.2.3.6 Rest of Asia-Pacific
-
-
5.2.4 Middle-East and Africa
-
5.2.4.1 GCC
-
5.2.4.2 South Africa
-
5.2.4.3 Rest of Middle-East and Africa
-
-
5.2.5 South America
-
5.2.5.1 Brazil
-
5.2.5.2 Argentina
-
5.2.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Cumberland Pharmaceuticals Inc.
-
6.1.2 Mallinckrodt Pharmaceuticals
-
6.1.3 New Medicon Pharma Lab
-
6.1.4 Becton, Dickinson and Company
-
6.1.5 Edwards Lifesciences Corporation
-
6.1.6 Aetna Inc.
-
6.1.7 Baxter
-
6.1.8 Fuji Systems Corp
-
6.1.9 Johnson & Johnson Co
-
6.1.10 G Surgiwear Ltd
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Hepatorenal Syndrome Treatment Industry Segmentation
Hepatorenal syndrome is the development of renal failure in patients with advanced chronic liver disease. This report is segmented by treatment, and by geography.
| By Treatment | |
| Therapeutics | |
| Liver Transplantation | |
| Surgical Shunting | |
| Renal Replacement Therapy | |
| Other Treatments |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hepatorenal Syndrome Treatment Market Research FAQs
What is the current Hepatorenal Syndrome Treatment Market size?
The Hepatorenal Syndrome Treatment Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)
Who are the key players in Hepatorenal Syndrome Treatment Market?
Cumberland Pharmaceuticals Inc. , Mallinckrodt Pharmaceuticals, New Medicon Pharma Lab, Becton, Dickinson and Company and Edwards Lifesciences Corporation are the major companies operating in the Hepatorenal Syndrome Treatment Market.
Which is the fastest growing region in Hepatorenal Syndrome Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Hepatorenal Syndrome Treatment Market?
In 2024, the North America accounts for the largest market share in Hepatorenal Syndrome Treatment Market.
What years does this Hepatorenal Syndrome Treatment Market cover?
The report covers the Hepatorenal Syndrome Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hepatorenal Syndrome Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Hepatorenal Syndrome Treatment Industry Report
Statistics for the 2024 Hepatorenal Syndrome Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hepatorenal Syndrome Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
